Mizuho Securities Starts Fate Therapeutics (FATE) at Buy
Tweet Send to a Friend
Mizuho Securities analyst Mara Goldstein initiates coverage on Fate Therapeutics (NASDAQ: FATE) with a Buy rating and $27 price target.The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
